Key topics from day 2 of the 10th International Workshop on Non-Hodgkin's Lymphoma

Share :
Published: 26 Sep 2012
Views: 10939
Rating:
Save
Dr Wyndham Wilson - National Cancer Institute, Bethesda, MD, USA; Prof. Owen O’Conner – New York University Cancer Institute and Lagone Medical Centre; Dr Myron Czuczman - Roswell Park Cancer Institute, Buffalo, NY, USA; Prof John Gribben - Bart’s and

The panel discuss the key points that emerged from the second day of the 10th iwNHL meeting in Boston. The topics discussed include T-cell-mediated immunotherapy with a chimeric antigen receptor (CAR), the identification of defects in epigenetic pathways associated with follicular lymphoma, the potential benefits of lenalidomide to different lymphoma sub-types and probable beneficial and adverse effects of drugs that target NF-κB.

 

In addition, the panel address concerns regarding the regulation of bio-similar versions of biological agents, discuss the toxicities associated with immunotherapies, including the potential long term reduction of patient B-cell levels, outline the potential costs and benefits of chronic treatment with ECR receptor signalling drugs and explain the approaches taken to reduce toxicities of the BiTE monoclonal antibody blinatumomab.